The SBIR and STTR federal seed funding programs—essential to many biotech start-ups—have been updated with important changes that provide new opportunities to applicants. These […]
National Cancer Institute explainer for CSBA: Why and how to apply for SBIR Read More »
BIO 2026 Start-Up Stadium winner generates human data to improve clinical translation. Artificial intelligence is opening new possibilities for drug discovery. But in neuroscience,
BrainStorm Therapeutics combines brain organoids and AI for CNS drug discovery Read More »
The BIO 2026 Start-up Stadium winner targets a rare disease. As Herb Sarnoff sits in the hospital, waiting for a pain specialist to see
iNFixion seeks NF1 treatment by enhancing what the body is doing right Read More »
For decades, Congress has passed legislation to protect Americans from public health emergencies, ranging from national security threats to disease outbreaks and natural disasters,
A national security priority: BIO pushes PAHPA reauthorization in 2026 Read More »
With tariffs on patented pharmaceuticals and input materials set to take effect for all companies on Sept. 29, the lack of clarity about rules
With pharmaceutical tariffs looming, guidance on compliance is still lacking Read More »
Stronger intellectual property protection statistically correlates with increased development of cutting-edge therapies and greater investment in life sciences research, according to a closely watched
Strong IP ecosystems drive biotech R&D and investment, report shows Read More »
“Context around patient-identified affordability and access challenges is really critical,” began Karin Hoelzer, DVM, PhD, Senior Director, Patient Advocacy during the Biotechnology Innovation Organization’s
Affordability and Access: Why patient perspectives matter Read More »
For years, advocates have pushed for more research and investment in women’s health. Now, it may be paying off. “I’m excited about the medicine
BIO 2026: Are we entering the ‘golden era’ of women’s health? Read More »
A Food and Drug Administration (FDA) pilot program to expedite approval of new drugs contains potentially impactful initiatives but risks adding burdens, says the
BIO applauds efforts targeting early drug development efficiency, provides suggestions Read More »
An agreement designed to shape the future of drug approval recommends new efficiencies while leaning into the existing strengths of a system that makes
PDUFA letter stresses stability, transparency, maturity, says BIO negotiator Read More »
